Moreover, we show for the first time that inhibiting MST1 with pharmacological agents, such as XMU-MP-1, represents a novel translational approach to prevent the occurrence of DOX-induced cardiomyopathy. This evidence concerns the gene MST1 and cardiomyopathy.